Cargando…
Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
OBJECTIVES: First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a sele...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter Open
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936471/ https://www.ncbi.nlm.nih.gov/pubmed/27847881 http://dx.doi.org/10.4103/2224-4018.154291 |
_version_ | 1782441568316162048 |
---|---|
author | Grigorescu, Alexandru C. |
author_facet | Grigorescu, Alexandru C. |
author_sort | Grigorescu, Alexandru C. |
collection | PubMed |
description | OBJECTIVES: First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a selected group of patients treated in Institute of Oncology Bucharest (IOB). MATERIALS AND METHODS: The study makes a clinical analysis of medical records of 27 patients from the archive of Institute of Oncology Bucharest treated by the same doctor. Patients were selected according to: age ≥ 65 years, ECOG performance status 0–1, normal blood counts and blood biochemistry, histological confirmation of the diagnosis of cancer, patients should received at least 3 cycles of chemotherapy. We extract characteristics of the patients to see if they were a homogeneous group of patients and to compare them with data from the literature. Overall survival was calculated by the Kaplan Meyer curve. RESULTS: 295 patients more then 65 years were treated in our site in 2 years 2011, 2012. 93 patients received chemotherapy and only 27 patients were enrolled in this study following inclusion criteria. Common sites of cancer were lung and breast. The most used cytostatics for lung cancer was gemcitabine and carboplatine and cyclophosphamide, metotrexat and 5 fluorouracil for breast cancer. Toxicity was mild with the prevalence of hematologic toxicity. Overall survival without taking into account the type of cancer was 27.7 month. CONCLUSIONS: For selected patients, chemotherapy was well tolerated and appears to prolong survival regardless of the location of cancer. The relatively small number of elderly patients who received chemotherapy is probably due to lack of compliance to treatment, the increased number of co-morbidities and evaluation of performance status only by the ECOG index known not to be good enough to establish the indication of chemotherapy. |
format | Online Article Text |
id | pubmed-4936471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | De Gruyter Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-49364712016-11-15 Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest Grigorescu, Alexandru C. J Transl Int Med Original Article OBJECTIVES: First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a selected group of patients treated in Institute of Oncology Bucharest (IOB). MATERIALS AND METHODS: The study makes a clinical analysis of medical records of 27 patients from the archive of Institute of Oncology Bucharest treated by the same doctor. Patients were selected according to: age ≥ 65 years, ECOG performance status 0–1, normal blood counts and blood biochemistry, histological confirmation of the diagnosis of cancer, patients should received at least 3 cycles of chemotherapy. We extract characteristics of the patients to see if they were a homogeneous group of patients and to compare them with data from the literature. Overall survival was calculated by the Kaplan Meyer curve. RESULTS: 295 patients more then 65 years were treated in our site in 2 years 2011, 2012. 93 patients received chemotherapy and only 27 patients were enrolled in this study following inclusion criteria. Common sites of cancer were lung and breast. The most used cytostatics for lung cancer was gemcitabine and carboplatine and cyclophosphamide, metotrexat and 5 fluorouracil for breast cancer. Toxicity was mild with the prevalence of hematologic toxicity. Overall survival without taking into account the type of cancer was 27.7 month. CONCLUSIONS: For selected patients, chemotherapy was well tolerated and appears to prolong survival regardless of the location of cancer. The relatively small number of elderly patients who received chemotherapy is probably due to lack of compliance to treatment, the increased number of co-morbidities and evaluation of performance status only by the ECOG index known not to be good enough to establish the indication of chemotherapy. De Gruyter Open 2015 2015-03-30 /pmc/articles/PMC4936471/ /pubmed/27847881 http://dx.doi.org/10.4103/2224-4018.154291 Text en Copyright © International Society of Translational Sciences This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License (CC BY-NC-ND 3.0) (http://creativecommons.org/licenses/by-nc-nd/3.0/) |
spellingShingle | Original Article Grigorescu, Alexandru C. Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest |
title | Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest |
title_full | Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest |
title_fullStr | Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest |
title_full_unstemmed | Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest |
title_short | Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest |
title_sort | chemotherapy for elderly patients with advanced cancer: a pilot study in institute of oncology bucharest |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936471/ https://www.ncbi.nlm.nih.gov/pubmed/27847881 http://dx.doi.org/10.4103/2224-4018.154291 |
work_keys_str_mv | AT grigorescualexandruc chemotherapyforelderlypatientswithadvancedcancerapilotstudyininstituteofoncologybucharest |